Production, biopharmaceutical
manufacturers have been reported to outsource more than 30% of their fill /
finish operations to contract service providers. Owing to the benefits, such as
inherent safety and ease-of-use, and provisions to reduce dosing errors, risk
of occlusions, extravasation and phlebitis, several injectable drugs (Humira®,
Enbrel®, Avastin®, PREVNAR 13®, ALPROLIX® and Benefix®), diluents and other
products requiring parenteral administration, are packaged in prefilled
syringes.
To order this 260+ page report, which features 60+ figures
and 110+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/prefilled-syringe-fill-finish-services/301.html
The USD 3 billion (by 2030) financial opportunity
within the prefilled syringe fill / finish services market has been analyzed
across the following segments:
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
§
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Landscape
5. Prefilled Syringe
Fill / Finish Service Providers in North America: Company Profiles
6. Prefilled
Syringe Fill / Finish Service Providers in Europe: Company Profiles
7. Prefilled
Syringe Fill / Finish Service Providers in Asia-Pacific: Company Profiles
8. Prefilled Syringe
Fill / Finish Service Providers: Recent Developments
9. Capacity Analysis
10. Demand Analysis
11. Geographical
Assessment of Demand and Supply
12. Likely Partner
Analysis
13. Market Sizing
and Opportunity Analysis
14. Future Growth
Opportunities
15. Case Study:
Prefilled Syringe Manufacturers
16. Concluding
Remarks
17. Interview Transcripts
18. Appendix 1:
Tabulated Data
19. Appendix 2:
List of Companies
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/prefilled-syringe-fill-finish-services/301.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
